Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes
Frontiers in Cellular and Infection Microbiology · 28.05.2026 · 16
DOI: 10.3389/fcimb.2026.1851763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 28.05.2026. Verfasst von Pengfei She und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha, China. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents, Drug Repositioning, Staphylococcal Infections. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Methicillin-resistant Staphylococcus aureus (MRSA) is frequently observed in biofilm form, exhibiting significant tolerance, particularly in the context of deep tissue infections such as osteomyelitis. This characteristic renders clinical treatment extremely challenging. Therefore, the development of novel antibacterial agents against MRSA and its biofilms is identified as an urgent priority.
Methods
By drug repurposing, this study determines the antibacterial activity of the anti-amoebic small molecule tiliquinol against MRSA and its highly drug-resistant biofilms and evaluates its potential to induce MRSA resistance. The antibacterial mechanism of tiliquinol is examined utilizing transcriptomics, fluorescent probes, and quantitative reverse-transcription polymerase chain reaction. In addition, we evaluate in vivo antibacterial efficacy and safety profiles by established multiple murine infection models, including skin and soft tissue infection, sepsis, as well as the periprosthetic joint infection.
Results
The research find that tiliquinol exhibits notable antibacterial activity against MRSA and its highly resistant biofilms avoiding resistance occurrence. Mechanism study reveals that the proton motive force and peptidoglycan are potential therapeutic targets by tiliquinol. Further, in various mouse infection models, favorable in vivo antibacterial efficacy with satisfied safety profiles of tiliquinol are confirmed.
Conclusion
Tiliquinol is recognized as a novel therapeutic strategy against refractory MRSA-related infections, particularly those associated with osteomyelitis and implant-related complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
- Department of Laboratory Medicine, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, China.
- Graduate Collaborative Training Base of The First Hospital of Changsha, of Hengyang Medical College, University of South China, Hengyang, China.
- Department of Laboratory Medicine, The Xiangya Hospital of Central South University, Changsha, China.
Zitieren
APA
She, P., Xiao, D., Huang, G., Guo, S., Liu, Y., Li, M., Lu, L., Hong, Y., & Wu, Y. (2026). Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1851763
Vancouver
She P, Xiao D, Huang G, Guo S, Liu Y, Li M, et al. Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1851763
BibTeX
@article{She2026,
author = {She, Pengfei and Xiao, Dan and Huang, Guanqing and Guo, Shaowei and Liu, Yiqing and Li, Mengna and Lu, Lihua and Hong, Yelan and Wu, Yong},
title = {Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1851763}
}
EUVIMED